Sanofi and Regeneron eye extending Dupixent US patent to 2033
Market talk says Sanofi and Regeneron could extend Dupixent’s U.S. patent by two years to 2033, with RBC Capital Markets citing a 70% chance in a research note.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.